May Hill Capital’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.64M Buy
25,093
+2,705
+12% +$252K 0.52% 38
2026
Q2
$1.68M Buy
22,388
+40
+0.2% +$2.57K 0.35% 56
2026
Q1
$1.26M Hold
22,348
– – 0.32% 65
2025
Q4
$1.79M Hold
22,348
– – 0.48% 41
2025
Q3
$1.09M Buy
22,348
+4,431
+25% +$274K 0.32% 53
2025
Q2
$1.34M Sell
17,917
-23
-0.1% -$1.52K 0.44% 44
2025
Q1
$1.14M Buy
17,940
+25
+0.1% +$1.7K 0.43% 41
2024
Q4
$1.4M Buy
+17,915
New +$1.44M 0.54% 31

Other funds holding HAE

May Hill Capital's HAE Position: Q3 2026 in Review

May Hill Capital increased its Haemonetics (HAE) stake by 12% in Q3 2026, buying an estimated $252K and bringing the position to 25,093 shares worth $2.64M. The position accounts for 0.52% of the portfolio, ranked #38.

May Hill Capital first reported a position in HAE in Q4 2024 and has held it in 8 quarters since. 358 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

  • May Hill Capital held 25,093 shares of Haemonetics worth $2.64M as of Q3 2026.
  • May Hill Capital bought 2,705 Haemonetics shares in Q3 2026, an estimated $252K.
  • Haemonetics made up 0.52% of May Hill Capital's portfolio in Q3 2026, its #38 holding.
  • May Hill Capital first reported a position in Haemonetics in Q4 2024 and has held it in 8 quarters since.
  • 358 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on May Hill Capital's 13F filing for Q3 2026, filed 3 Nov 2026.